Marie Thibault
Stock Analyst at BTIG
(3.82)
# 2,401
Out of 4,828 analysts
72
Total ratings
51.47%
Success rate
8.09%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.65 | +352.83% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $11.97 | +117.21% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $310.67 | -13.09% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $156.57 | +8.58% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $33.92 | +91.63% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $102.86 | -9.59% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $68.19 | +64.25% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $31.00 | +70.97% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $84.67 | +41.73% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.20 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.43 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $14.84 | +34.77% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $137.70 | +1.67% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.60 | -16.67% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $133.24 | -6.18% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.51 | +363.58% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.43 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.63 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $190.01 | -96.84% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.65
Upside: +352.83%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $11.97
Upside: +117.21%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $310.67
Upside: -13.09%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $156.57
Upside: +8.58%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $33.92
Upside: +91.63%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $102.86
Upside: -9.59%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $68.19
Upside: +64.25%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $31.00
Upside: +70.97%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $84.67
Upside: +41.73%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.20
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.43
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $14.84
Upside: +34.77%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $137.70
Upside: +1.67%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.60
Upside: -16.67%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $133.24
Upside: -6.18%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.51
Upside: +363.58%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.43
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.63
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $190.01
Upside: -96.84%